Skip to main content

Table 3 Treatment related toxicities

From: Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Treatment-related AE

No. (%) of events

 
 

Any Grade

Grade 3–4

Any

8(100%)

3(37.5%)

Fatigue

6(75.0%)

0

Asthenia

5(62.5%)

0

Nausea

3(37.5%)

1(12.5%)

Decreased appetite

5(62.5%)

1(12.5%)

Diarrhea

2(25.0%)

0

Dry mouth

5(62.5%)

0

Vomiting

3(37.5%)

1(12.5%)

Rash

7(87.5%)

0

Pruritus

6(75.0%)

0

Anemia

2(25.0%)

0

Pneumonia

1(12.5%)

0

Neutropenia

1(12.5%)

0

Myalgia

0

0

Autoimmune hepatitis

0

0

Dyspnoea

0

0